TKI

TKI Discontinuation for Patients With CML Could Save Billions

TKI Discontinuation for Patients With CML Could Save Billions

By

With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.

TKI-treated Patients With CML May Have Increased Risk of Vascular Events

TKI-treated Patients With CML May Have Increased Risk of Vascular Events

By

Patients with chronic myeloid leukemia (CML) treated with a first- or second-generation tyrosine kinase inhibitor (TKI) may have an increased risk of arterial and venous vascular events.

Cabozantinib Not Superior to Prednisone for Pretreated mCRPC

Cabozantinib Not Superior to Prednisone for Pretreated mCRPC

By

When compared to prednisone, cabozantinib failed to improve overall survival of heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).

Ponatinib Induces Durable Responses in Patients With CML for at Least 4 Years

Ponatinib Induces Durable Responses in Patients With CML for at Least 4 Years

By

Ponatinib resulted in durable responses after 4 years in heavily pretreated patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Ribociclib Improves PFS in Treatment-naïve Patients With Advanced Breast Cancer

Ribociclib Improves PFS in Treatment-naïve Patients With Advanced Breast Cancer

By

Adding ribociclib to letrozole significantly prolonged progression-free survival compared with letrozole alone in postmenopausal women.

Post-transplant Maintenance TKI Therapy Feasible for High-risk Ph+ Leukemia

Post-transplant Maintenance TKI Therapy Feasible for High-risk Ph+ Leukemia

By

Post-transplant maintenance TKI therapy is feasible and could be beneficial for patients with high-risk Philadelphia chromosome-positive leukemia.

Researchers Identify Risk Factors for Bosutinib-related Cardiac, Vascular Toxicities

Researchers Identify Risk Factors for Bosutinib-related Cardiac, Vascular Toxicities

By

Researchers sought to evaluate cardiac and vascular toxicities associated with long-term bosutinib treatment in patients with Ph-positive leukemia.

Subgroup Analyses Show Cabozantinib Improves PFS, ORR in Advanced RCC

Subgroup Analyses Show Cabozantinib Improves PFS, ORR in Advanced RCC

By

New study data indicates that patients with previously treated advanced kidney cancer may benefit more from cabozantinib than from everolimus.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs